2,404
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Evaluation

Rapid Systemic Delivery of Zolmitriptan Using an Adhesive Dermally Applied Microarray

, &
Pages 559-567 | Received 08 Jun 2017, Accepted 10 Jul 2017, Published online: 25 Jul 2017

Figures & data

Figure 1. Adhesive Dermally-Applied Microarray (ADAM) with zolmitriptan-coated titanium microprojections.

Left panel depicts the assembled ADAM. Right shows a scanning electron micrograph of the zolmitriptan-coated microprojections.

Figure 1. Adhesive Dermally-Applied Microarray (ADAM) with zolmitriptan-coated titanium microprojections.Left panel depicts the assembled ADAM. Right shows a scanning electron micrograph of the zolmitriptan-coated microprojections.
Figure 2. Adhesive Dermally-Applied Microarray application.

ADAM: Adhesive Dermally-Applied Microarray.

Figure 2. Adhesive Dermally-Applied Microarray application.ADAM: Adhesive Dermally-Applied Microarray.
Figure 3. Adhesive Dermally-Applied Microarray patch ring assembly.

ADAM: Adhesive Dermally-Applied Microarray.

Figure 3. Adhesive Dermally-Applied Microarray patch ring assembly.ADAM: Adhesive Dermally-Applied Microarray.
Figure 4. Schematic of drug delivery using the Adhesive Dermally-Applied Microarray.
Figure 4. Schematic of drug delivery using the Adhesive Dermally-Applied Microarray.
Figure 5. Pharmacokinetic study schema.
Figure 5. Pharmacokinetic study schema.

Table 1. Study treatments.

Table 2. Participant demographics and baseline characteristics.

Figure 6. Concentration–time curves following administration of zolmitriptan with the Adhesive Dermally-Applied Microarray or subcutaneous sumatriptan.

(A) Zolmitriptan groups A, B, C, D, F, G, zero to 24 h (B) Zolmitriptan groups A, B, C, D, F, G, zero to 2 h (C) Sumatriptan group E, zero to 24 h (D) Sumatriptan group E, zero to 2 h.

Figure 6. Concentration–time curves following administration of zolmitriptan with the Adhesive Dermally-Applied Microarray or subcutaneous sumatriptan. (A) Zolmitriptan groups A, B, C, D, F, G, zero to 24 h (B) Zolmitriptan groups A, B, C, D, F, G, zero to 2 h (C) Sumatriptan group E, zero to 24 h (D) Sumatriptan group E, zero to 2 h.

Table 3. Plasma pharmacokinetic parameters.

Table 4. Intergroup pairwise comparisons of AUC2h.

Table 5. Adverse events with incidence ≥1.

Table 6. Application site assessments at 30 min and 24 h after removal of the Adhesive Dermally-Applied Microarray.